It will compete with Eisai and Biogen's Leqembi, which the FDA approved last year ... Go deeper: Where the future of Alzheimer's drugs is heading Get more health news in your inbox with Axios ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

The FDA confirmed ... with Alzheimer’s get their health coverage through Medicare. And private insurers have followed its lead by withholding coverage for Leqembi and a similar drug, Aduhelm ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

WASHINGTON--U.S. officials have approved another Alzheimer’s drug ... get the drugs and how long they might benefit. The new drug’s approval was expected after an outside panel of FDA ...

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University report that they were able to successfully put tadpoles of Xenopus laevis frogs into a hibernation-like ...

However, there is no way to predict who will get a benefit ... the only generic drug specifically approved by the FDA for treatment of middle-stage and late-stage Alzheimer's (Namenda is also ...

The firms that are overdue for safety and quality inspections represent about 42% of the 4,700 plants that are currently ...

NASHVILLE, Tenn. (WSMV) - KCA Neurology in Middle Tennessee has recently launched a National Institutes of Health-funded ...

Eli Lilly received FDA breakthrough status for its donanemab Alzheimer's drug, speeding the agency's review of the product. The shares are higher. Eli Lilly (LLY) shares rose Thursday after ...

Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in ...